Our mission is to isolate and develop antibodies from cured cancer survivors to create safe, effective and targeted therapies for other cancer patients. We believe our approach has the potential to leverage the cancer fighting success of others to bring deep and sustained anti-cancer benefits to many.
This therapeutic approach is being increasingly recognized by the scientific community. Recent scientific breakthroughs have demonstrated that the presence and generation of immune B-cells (that secrete antibodies) in the tertiary lymphoid structures of tumors of cancer patients support and predict response to immune checkpoint inhibitors.
Using our proprietary technology platform, we interrogate the full B-cell repertoire from cured cancer patients and reverse-engineer their successful immune response. Our antibody expertise was first evolved and perfected for infectious disease applications. From that history and experience, we demonstrated a proven track-record of selecting and isolating therapeutic antibodies directly from patients with infectious disease, elucidating the unique potential of patient-derived antibodies.
Similarly in cancer, we have successfully identified and isolated reactive antibodies from cancer survivors. Once identified, these novel antibodies are quickly advanced through discovery and lead optimization. Our proprietary approach allows us to unlock novel targets and advance new science, resulting in a revolutionary, paradigm shift in immune-oncology.
AIMM works closely with its (academic) partners to bring these promising therapeutic candidates to patients.